OX-201
OX-201 is an orally active, blood-brain barrier-permeable OX2R agonist with an EC50 of 8.0 nM. OX-201 activates OX2R to induce wakefulness and neuronal activation. OX-201 promotes the release of neuron activity-dependent tau protein from neurons into the interstitial fluid of hippocampal tissues. OX-201 is applicable to research related to Alzheimer's disease and tauopathies.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2460722-03-4
- 分子式: C22H23F5N2O4S
- 分子量:506.49
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Orexin Receptor (OX Receptor) アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
|
OX2 Receptor 8 nM (EC50) |
OX1 Receptor 8.1 μM (EC50) |
体外実験
OX-201 (8.0 nM-10 μM) is a potent, highly selective OX2R agonist with minimal off-target activity in cell-based in vitro assays[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
OX-201 (3-30 mg/kg; p.o.; single administration or once daily for consecutive 2 months) enhances wakefulness during the active phase in male human P301S tau transgenic mice; at the dose of 30 mg/kg, it induces neuronal activation and increases interstitial fluid (ISF) tau levels in the hippocampus, while the regimen of 30 mg/kg once daily for consecutive 2 months does not exacerbate hippocampal tau aggregation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 8-12 weeks old)[1]
-
Dosage:10 mg/kg; 30 mg/kg; 100 mg/kg
-
Administration:p.o.; single dose
-
Result:Significantly increased total wakefulness time over 6 hours post-administration during the sleep phase, with dose-dependent effects.
Showed a non-significant tendency to increase hippocampal ISF tau levels for 4.5 hours at 100 mg/kg.
Significantly increased hippocampal ISF lactate levels for 7.5 hours at 100 mg/kg.
Had no clear effect on hippocampal ISF glucose levels at 100 mg/kg.
-
Animal Model:human P301S tau transgenic (Tg) (male, 7-9 months old, tauopathy model)[1]
-
Dosage:3 mg/kg; 10 mg/kg; 30 mg/kg (single dose wakefulness/ISF studies); 30 mg/kg (chronic 2-month tau accumulation study)
-
Administration:p.o.; single dose; once daily for 2 months
-
Result:Significantly increased total wakefulness time during the 6-hour window post-administration (ZT13-18) during the active phase, with no residual effect on wakefulness during the subsequent sleep phase, at 3, 10, and 30 mg/kg.
Increased hippocampal ISF tau levels for > 16.5 hours at 30 mg/kg.
Increased ISF lactate levels for >6 hours at 30 mg/kg.
Increased ISF glucose levels at 30 mg/kg.
Did not alter total hippocampal tau levels after chronic once-daily administration of 30 mg/kg for 2 months.
化学情報
-
CAS 番号 2460722-03-4
-
分子量 506.49
-
分子式 C22H23F5N2O4S
-
SMILES
FC1=C(C2=CC(F)=CC(F)=C2)C=CC=C1C[C@]3([H])N(C(C(O)(C)C)=O)CC(F)(F)[C@]3([H])NS(=O)(C)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
OX-201 関連分類
HY-162712 関連分類
Powered by Bioz